DCPrime BV has entered into a research and optional license agreement with Janssen Pharmaceuticals, in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business and science members identify and build novel early-stage collaborations with emerging companies.   Janssen will utilize DCPrime’s DCOne technology in feasibility studies for the development of a dendritic cell-based vaccine for which it will have the option to further develop towards regulatory approva...